Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Zimmer Biomet realigns Americas and portfolio leadership around go-to-market, robotics and technology while confirming its previously issued 2026 outlook.
Rhea-AI Summary
Zimmer Biomet (ZBH) announced several Americas leadership promotions and a restructuring of its commercial organization effective October 1, 2026.
Gary Campbell will become President, Americas, overseeing commercial strategy and execution in the United States, Canada and Latin America and continuing to evolve the U.S. go-to-market model. Brian Hatcher will be promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, expanding his remit to include Global Knees and Hips and leading global portfolio strategy across most of the company’s businesses. Bradley Kessler will become President, Americas – Robotics, Technology and Data, responsible for driving robotics, digital and technology solutions in the Americas and supporting the anticipated 2027 launch of the Monogram next-generation orthopedic robot.
As part of the restructuring, Kevin Thornal, Group President, Global Businesses and the Americas, will leave the company on September 30, 2026. Zimmer Biomet also reiterated its full-year 2026 financial outlook previously provided on August 5, 2026.
Positive
- Full-year 2026 financial outlook is reiterated, matching guidance provided on August 5, 2026.
- Creation of a dedicated President, Americas – Robotics, Technology and Data role to drive adoption of digital and robotic solutions.
- New President, Americas role centralizes U.S., Canada and Latin America commercial strategy and execution.
Negative
- Group President, Global Businesses and the Americas Kevin Thornal will leave the company on September 30, 2026.
Key Figures
- Promotion effective date
- October 1
- Americas and global business leadership appointments
- Executive departure date
- September 30
- Kevin Thornal leaves the company after a transition period
- Expected robot launch
- 2027
- Monogram next-generation orthopedic robot
Historical Context
-
Chintan Desai was appointed president of the Asia Pacific region
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Gary Campbell promoted to President,
Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery
Bradley Kessler promoted to President,
WARSAW, Ind., Sept. 8, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced leadership appointments designed to streamline its
Effective October 1, Gary Campbell will be promoted to President,
"We talk often about our People and Culture strategic imperative to have the right talent, in the right roles, at the right times," said Tornos. "These well-deserved promotions do exactly that, while helping to accelerate our
As part of this restructuring, Kevin Thornal, Group President, Global Businesses and the
Tornos added, "On behalf of the entire Zimmer Biomet team, I want to thank Kevin for his leadership and contributions to our company. We wish him all the best in his next chapter."
2026 Outlook
Zimmer Biomet also announced today that the Company is reiterating its full-year 2026 financial outlook provided on August 5, 2026.
About Gary Campbell
As President,
Campbell has served as Zimmer Biomet's vice president and general manager, Orthopedics –
About Brian Hatcher
As President, Recon, S.E.T., CMFT, Neuro and Biosurgery, Hatcher will lead global portfolio strategy and execution across most of the company's businesses, expanding his current remit to include Global Knees and Hips. He will continue to play an integral role in the company's innovation and diversification strategy, including delivering organic and inorganic opportunities in higher growth markets. Lou Galrao, President of Reconstruction (Knees and Hips), will report to Hatcher.
During his 16-year career with Zimmer Biomet, Hatcher has held multiple roles in research, marketing, general management and business leadership. He was named to his first Global President role in 2021 and currently serves as Zimmer Biomet's President of S.E.T. and CMFT. Hatcher began his medical technology career with roles at OrbusNeich and later Medtronic. He holds a bachelor's degree in chemistry and a Ph.D. in biomedical engineering, both from the University of
About Brad Kessler
As President,
Kessler brings to the role more than two decades of commercial experience in orthopedics. Currently vice president and general manager, Robotics, Technology and Data Solutions, Kessler has held multiple commercial leadership roles of increasing responsibility since he joined Zimmer Biomet in 2015. Prior to joining Zimmer Biomet, Kessler spent nearly 10 years in sales at Stryker. He holds a bachelor's degree from Texas A&M University and an Executive MBA from the Cox School of Business at Southern Methodist University.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, outlook, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission ("SEC"). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
Contacts: Media Troy Kirkpatrick 614-284-1926 troy.kirkpatrick@zimmerbiomet.com
781-779-5561 | Investors David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com
908-591-6955 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-americas-leadership-promotions-to-accelerate-commercial-transformation-302872765.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
When do the leadership changes at Zimmer Biomet take effect?
The promotions of Gary Campbell to President, Americas, Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, and Brad Kessler to President, Americas – Robotics, Technology and Data are effective October 1, 2026. As part of the same restructuring, Kevin Thornal will leave the company on September 30, 2026 following a transition period.
What will Gary Campbell oversee as President, Americas?
As President, Americas, Gary Campbell will be responsible for commercial strategy and execution across the United States, Canada and Latin America. He will continue to lead the evolution of Zimmer Biomet’s U.S. go-to-market model, including building a specialized and dedicated organization intended to increase productivity and accelerate growth.
How does Brian Hatcher’s role change in this restructuring?
Brian Hatcher becomes President, Recon, S.E.T., CMFT, Neuro and Biosurgery, where he will lead global portfolio strategy and execution across most of Zimmer Biomet’s businesses and expand his remit to include Global Knees and Hips. Lou Galrao, President of Reconstruction (Knees and Hips), will report to Hatcher, who will continue contributing to the company’s innovation and diversification strategy.
What are Brad Kessler’s responsibilities as President, Americas – Robotics, Technology and Data?
As President, Americas – Robotics, Technology and Data, Brad Kessler will drive commercial strategy, growth and adoption of Zimmer Biomet’s robotics, digital and technology portfolio in the Americas. He will also oversee the company’s global service and capital solutions contracting business, and under his leadership the company plans to accelerate expansion of its specialized robotics salesforce ahead of the expected 2027 launch of the Monogram next-generation orthopedic robot.
What did Zimmer Biomet say about its 2026 financial outlook?
Zimmer Biomet stated that it is reiterating its full-year 2026 financial outlook that was previously provided on August 5, 2026. No changes to that guidance were announced in this release.